Small for gestation and growth hormone therapy.

Area of Science:

• Pediatrics
• Endocrinology
• Genetics

Background:

• 3-10% of neonates are born small for gestational age (SGA), often due to intrauterine growth retardation (IUGR).
• While most SGA infants experience catch-up growth, approximately 10% remain short, leading to potential psychosocial issues.
• The underlying mechanisms for persistent short stature in SGA infants are not fully understood, but often involve alterations in the growth hormone-IGF-I axis.

Purpose of the Study:

• To review the diagnostic and management criteria for short stature in SGA infants.
• To evaluate the efficacy and safety of growth hormone (GH) therapy for improving adult height in SGA children.
• To understand the impact of GH therapy on normalizing height and addressing psychosocial concerns in this population.

Main Methods:

• Review of existing literature and clinical guidelines regarding SGA and short stature.
• Analysis of data on growth hormone (GH) therapy outcomes in SGA children.
• Assessment of safety profiles and monitoring recommendations for GH treatment.

Main Results:

• Growth hormone (GH) therapy is FDA-approved for improving height in SGA children.
• GH treatment promotes growth acceleration and height normalization during childhood.
• Long-term GH therapy normalizes adult height above -2 SDS in 85% of SGA children, with 98% achieving their target height range.

Conclusions:

• Growth hormone (GH) therapy is a safe and effective treatment for normalizing adult height in SGA children who do not achieve adequate growth.
• Monitoring for potential side effects is crucial during GH therapy.
• Improved diagnostic and management strategies are essential for addressing short stature in SGA populations.